Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.
Fiche du document
- doi: 10.1183/13993003.01916-2018
- issn: 0903-1936
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1183/13993003.01916-2018
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30545978
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1399-3003
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7F24E41BA1348
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Therapy Knowledge, Classification ofCiter ce document
E.B. Rosenzweig et al., « Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. », Serveur académique Lausannois, ID : 10.1183/13993003.01916-2018
Métriques
Partage / Export
Résumé
Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease, but is associated with several additional disorders and challenges that require unique approaches. This article discusses recent advances, ongoing challenges and distinct approaches for the care of children with PAH, as presented by the Paediatric Task Force of the 6th World Symposium on Pulmonary Hypertension. We provide updates of the current definition, epidemiology, classification, diagnostics and treatment of paediatric PAH, and identify critical knowledge gaps. Several features of paediatric PAH including the prominence of neonatal PAH, especially in pre-term infants with developmental lung diseases, and novel genetic causes of paediatric PAH are highlighted. The use of cardiac catheterisation as a diagnostic modality and haemodynamic definitions of PAH, including acute vasoreactivity, are addressed. Updates are provided on issues related to utility of the previous classification system to reflect paediatric-specific aetiologies and approaches to medical and interventional management of PAH, including the Potts shunt. Although a lack of clinical trial data for the use of PAH-targeted therapy persists, emerging data are improving the identification of appropriate targets for goal-oriented therapy in children. Such data will likely improve future clinical trial design to enhance outcomes in paediatric PAH.